Anti-CDH17 and anti-IL13Ra2 monoclonal antibodies developed by PROALT togheter with the Spanish Research Council (CSIC) are promising novel biological drugs to treat metastatic colorectal cancer (mCRC) and glioblastoma (GBM). Both could be new options for people whose cancers have not responded to previous lines of treatment. Delegates and Investors at the Anglonordic Life Science Conference held in London on May 5, heard from COO Juan Ignacio Imbaud, who showed the latest efficacy results in animals and explained the company aims to outperform currently used therapy limitations for colorectal cancer patient at late stage.